@inproceedings{inproceedings, title  = {{Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial}},

 publisher = {{American Society of Hematology}},

 url = {{}},

 year = {{2015}},

 month = {{12}},

 author = {{Ashcroft J and Cairns DA and Williams C and Hockaday A and Cavenagh JD and Snowden JA and Parrish C and Yong KL and Cavet J and Hunter H and Bird J et al}},

 doi = {{10.1182/blood.v126.23.1981.1981}},

 volume = {{126}},

 journal = {{Blood}},

 issue = {{23}},

 pages = {{1981-1981}},

 note = {{Accessed on 2024/12/22}}}